CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 60 target
Drug / intervention
Epigallocatechin gallate (EGCG) +1 moredrug
Likely dose
Not stated in record
Key inclusion· 7
  • ✓Adults 18 years or older
  • ✓Clinically and/or histologically diagnosed cirrhosis
  • ✓No active hepatic decompensation
  • ✓No prior history of HCC
Key exclusion· 6
  • ✕Prior or ongoing use of EGCG
  • ✕History of adverse reaction to green tea products
  • ✕Severe obesity (BMI >40 kg/m²)
  • ✕Active drinking

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06015022
NCT06015022Phase 2RecruitingOn TrackUpdated 9mo ago
CompareCT.gov

Phase II Randomized Controlled Trial of Epigallocatechin Gallate for Hepatocellular Carcinoma Chemoprevention

University of Texas Southwestern Medical Center·interventional·Posted Aug 29, 2023·Updated Sep 5, 2025

In Brief

A Phase 2 clinical trial evaluating Epigallocatechin gallate (EGCG) and Placebo for Cirrhosis, Liver. Currently recruiting, targeting 60 participants across 1 site.

Detailed Summary

This phase II trial tests epigallocatechin gallate (EGCG) for its efficacy and safety in preventing development of hepatocellular carcinoma (HCC) in patients with liver cirrhosis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCirrhosis, Liver
CountriesUnited States
Collaborators--

Timeline

Phase 2Recruiting
20242025202620272028
First PostedAug 29, 2023
Enrollment StartSep 1, 2024
Primary CompletionAug 31, 2028
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 2.8 years agoPrimary completion in 2.2 years

Interventions

Epigallocatechin gallate (EGCG)drug

EGCG is a green tea-derived catechin

Placeboother

Placebo in the same capsule with the experimental agent (EGCG).